Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 12/20 | 0.69 |
| ▸ | FNTA | P49354 | 1/20 | 0.51 |
| ▸ | FNTB | P49356 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 4/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916741 | 0.89 | FNTA (0.60) | CYP19A1FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL10464405 | 0.82 | CYP17A1 (0.53) | CYP19A1FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL6305490 | 0.78 | FNTA (0.81) | CYP19A1FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL10642922 | 0.78 | CYP19A1 (1.00) | CYP19A1CYP11B1CYP11B2CNR1CYP17A1 | |
| SCHEMBL10102766 | 0.76 | CYP19A1 (0.55) | CYP19A1FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL10464815 | 0.74 | CYP19A1 (0.57) | CYP19A1FNTAFNTBCNR1TBXAS1 | |
| SCHEMBL10461788 | 0.73 | CYP17A1 (0.50) | CYP19A1TBXAS1PDE3BPDE3ACYP17A1 | |
| SCHEMBL12337076 | 0.73 | CYP19A1 (0.53) | CYP19A1CYP11B1CYP11B2CYP17A1 | |
| SCHEMBL10477318 | 0.73 | CYP19A1 (0.55) | CYP19A1FNTAFNTBCYP11B1CYP11B2 | |
| SCHEMBL27262921 | 0.73 | CYP19A1 (0.62) | CYP19A1CYP11B1CYP11B2CNR1CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | claimed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | claimed |
| US-5612354-A | CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-03-18 | — | — | US | disclosed |
| US-5441954-A | Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells | JANSSEN PHARMACEUTICA N. V. (BE) | 1995-08-15 | — | — | US | disclosed |
| CN-1106005-A | A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-08-02 | — | — | CN | disclosed |
| EP-0371564-B1 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1995-07-12 | — | — | EP | disclosed |
| US-5268380-A | Therapy for keratinization in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-07 | — | — | US | disclosed |
| US-5185346-A | Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents | HANSSEN PHARMACEUTICA (BE) | 1993-02-09 | — | — | US | disclosed |
| CN-1042912-A | (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-06-13 | — | — | CN | disclosed |